UK pharmaceutical shares slipped 0.7% on Monday, handing back only a sliver of Friday's surge of more than 5%, while the FTSE 100 shrugged off the dip to post a fourth straight gain.

A small step back after a giant leap

On Friday 30 October, the FTSE 350 pharmaceuticals sector rose more than 5%. It was the sector's biggest daily gain in about 13 months. On Monday 2 November, it fell 0.7%.

Put those two moves side by side and the picture is clear: the pullback was modest. Most of Friday's gain remained intact at Monday's close. The reports covering the session did not attribute either Friday's surge or Monday's dip to specific company news, so the explanation here focuses on what the moves reveal about the market rather than on why they happened.

Illustration: Imagine a sector index standing at 100. A 5% rise takes it to 105 (100 × 1.05). A 0.7% fall the next day takes it to about 104.27 (105 × 0.993 = 104.265). After both moves, the index would still be about 4.3% above where it started. Friday's rise was more than 5%, so the real retained gain may be slightly higher; the figures are rounded and purely illustrative.

In market terms, that is a classic pause after a big move. Sharp one-day rallies are often followed by some profit-taking as traders lock in gains, and a sub-1% dip after a 5% jump falls comfortably within that pattern. It is not, on its own, evidence that sentiment towards the sector has turned. A genuine Reversal would usually show up as a run of losing sessions, or a fall large enough to erase most of the earlier gain, and neither had happened by Monday's close.

How the FTSE 100 coped without its healthcare tailwind

The more interesting question is what happened to the index while pharma took a breather. Because the FTSE 100 is weighted by market value, its large pharmaceutical constituents can move the headline figure noticeably. On Monday, they were not pulling it higher.

Neither was energy. Brent Crude fell to around $105 a barrel from $117.61 on Friday, on reports that Washington and Tehran were considering renewed indirect talks. Iranian Foreign Ministry spokesman Esmaeil Baghaei said "the ball is now in the US's court". The FTSE 350 energy sector dropped 3.3%. Ithaca Energy (LSE:ITH) was the FTSE 100's biggest faller, down 5.94%, while BP (LSE:BP.) lost 4.37% and Shell (LSE:SHEL) slipped 2.86%.

With two heavyweight sectors in reverse, the FTSE 100 still closed at 10,761.33, up 31.55 points, or about 0.3%, from Friday's 10,729.78. That marked a fourth straight session of gains. The index was essentially flat at midday, at 10,724.58, before recovering through the afternoon.

The lift came from elsewhere. Travel and leisure shares rose 2.7%, construction and materials gained 2.8%, and consumer goods and services added 2.5%. Reports linked that rally to cheaper oil, which promises lower transport and fuel costs for consumer-facing businesses. JD Sports Fashion (LSE:JD.) topped the FTSE 100 risers with a 4.76% gain, and International Consolidated Airlines Group (LSE:IAG) rose 3.8%. Gold's climb to $3,968.02 an ounce helped Fresnillo (LSE:FRES) add 4.56%.

That is the real message of Monday's session. The index's winning streak did not depend on any single sector. When pharma and energy paused or fell, other parts of the market took up the slack. Breadth of this kind is often seen as a healthier sign than a rally carried by a handful of giants, although one session does not establish a trend.

The mid-cap picture reinforced the point. The FTSE 250 rose 1.4% to 24,795.85, far outpacing the Blue-Chip index, as investors favoured more domestically focused companies. In Europe, the Stoxx 600 rose 0.42% to a two-month high, the CAC 40 gained about 1% and the DAX added 0.6%, suggesting the appetite for risk was not confined to London.

The week that will test the rotation

Whether Monday's rotation holds may depend on a dense run of events. Healthcare gets its own check-in on Wednesday 4 November, when Smith & Nephew (LSE:SN.) publishes a third-quarter trading statement. The medical technology group cut its full-year adjusted Revenue growth guidance to about 4% from 6% in August. It is a different Business from the drug makers, but its update will add to the sector conversation.

Rates are the bigger theme. The Bank of England announces its decision on Thursday 5 November, with markets pricing a roughly 95% chance of a quarter-point rise from 3.75% to 4%, the first in more than three years. UK Inflation rose faster than expected in September, and the October Manufacturing PMI rose to 52.8, a five-month high. Economists expect a 7–2 vote.

Large defensive sectors such as pharmaceuticals can respond differently to rate expectations than cyclical, consumer-facing ones. How investors read the Bank's message, including any pushback from Governor Andrew Bailey on further tightening, could shape whether money keeps flowing into travel, retail and housebuilding or drifts back towards defensives.

Income investors will note one more healthcare date. GSK (LSE:GSK) goes ex-dividend on a 17p quarterly payment on Thursday 12 November. The US midterm elections on Tuesday and US payrolls on Friday complete a crowded week.

Key dates to watch

  • Tuesday 3 November: US midterm elections
  • Wednesday 4 November: Smith & Nephew Q3 trading statement
  • Thursday 5 November: Bank of England rate decision
  • Friday 6 November: US October payrolls
  • Thursday 12 November: GSK ex-dividend (17p quarterly) and UK GDP first quarterly estimate for July to September

The bottom line

Monday's 0.7% dip in pharmaceutical shares gave back only a small fraction of Friday's rally of more than 5%, the sector's best day in about 13 months. More telling was the FTSE 100's response: with both pharma and energy in retreat, the index still rose 0.3% to a fourth straight gain, helped by travel, consumer and construction stocks. With a likely Bank of England rate rise on Thursday, investors will be watching whether that broader rally can keep going without a healthcare tailwind.